Compare UiPath Inc (PATH) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs DENTSPLY SIRONA Inc — how do they compare? UiPath Inc trades at $13.3 (market cap $6.81B), while DENTSPLY SIRONA Inc trades at $8.67 (market cap $1.70B). The key difference: UiPath Inc is far larger — about 4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| PATH | XRAY | |
|---|---|---|
Market Cap | $6.81B | $1.70B |
Volume | 22,766,109 | 4,220,050 |
Sector | Technology | Health |
52-Week High | $19.29 | $14.68 |
52-Week Low | $9.38 | $8.52 |
Typical Hold Time | 139 Days | 72 Days |
Enterprise Value | $5.61B | $3.78B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.07, down 0.23% on the day, amid a bearish technical signal and mixed earnings history. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to a projected $1.7B in 2026, while net income is expected to turn positive. Recent news highlights AI partnerships and product innovations, but the stock faces headwinds from cautious analyst sentiment and technical resistance.
The outlook for PATH is cautiously optimistic, with strong revenue growth and a path to profitability offering upside potential, but risks include execution challenges and competitive pressures. The consensus price target of $15.13 suggests moderate upside from current levels, though investor sentiment remains divided.
DENTSPLY SIRONA (XRAY) trades at $8.69, near its 52-week low, with bearish technical signals and declining revenue trends. The company reported Q2 2026 earnings beat but faces margin pressure and negative profitability metrics. Recent news highlights institutional stake increases and ongoing restructuring efforts amid challenging dental market conditions.
The stock presents a high-risk opportunity with analyst consensus target of $13.40 suggesting 54% upside potential. However, persistent net losses, declining revenue, and bearish technical indicators warrant caution. Recovery depends on successful execution of turnaround initiatives and market share stabilization in competitive dental equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
